Resiliva is a prescription medication (to be used alongside diet and exercise) to treat adults with nonalcoholic steatohepatitis (NASH) who have moderate to advanced liver fibrosis but not cirrhosis.
Resiliva is a generic version of Rezdiffra which is Resmetirom indicated for Non-alchoholic steatohepatitis (NASH).
As a Least Developed Country (LDC), Bangladesh received a special waiver under the WTO’s TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) until 2033. This allows Bangladesh to produce generic versions of patented drugs without paying royalties, significantly reducing manufacturing costs.
Take Resiliva orally once daily, with or without food, following your healthcare provider’s exact instructions. Your specific dosage will be determined based on your body weight to ensure optimal treatment effectiveness.
Answer: No. As a commitment to patient affordability, Everest Pharmaceuticals Ltd. proudly introduces Resiliva, the first global generic version of Resmetirom (Rezdiffra). This medication is now accessible to patients worldwide at a more affordable price. Contact us to learn more about availability and purchasing options.
Answer: The most common side effects of Resiliva include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.
Answer: Resmetirom is the first and only FDA-approved oral medication taken once daily for adults with NASH (non-alcoholic steatohepatitis) and liver fibrosis. Its USFDA approval is based on proven improvements in both NASH and liver scarring. Ongoing clinical studies aim to further validate its therapeutic benefits.
